A novel wearable platform to assess cognitive-motor performance

一种评估认知运动表现的新型可穿戴平台

• 批准号: 9556128
• 负责人: Bijan Najafi
• 金额: $ 40.28万
• 依托单位: BIOSENSICS, LLC
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-04-15 至 2020-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9556128
• 关键词: Academy; Acceleration; Age; Aging; Algorithms; Alzheimer' s Disease; Ankle; Applications Grants; Assessment tool; Clinic; Clinical; Clinical Research; Code; Cognitive; Computer software; Data; Decision Making; Dementia; Dependence; Development; Devices; Diagnosis; Educational Background; Effectiveness; Elderly; Engineering; Equilibrium; Funding; Future; Gait; Geriatrics; Gerontology; Goals; Government; Grant; Guidelines; Healthcare; Impaired cognition; Individual; Inpatients; Institutes; International; Legal patent; Measurement; Measures; Medical Device; Medical Technology; Medicine; Methods; Monitor; Motion; Motor; Names; Paper; Pathway interactions; Patient Education; Patients; Performance; Phase; Pilot Projects; Population; Psyche structure; Publishing; Research; Risk Assessment; Savings; Scanning; Screening procedure; Short-Term Memory; Small Business Technology Transfer Research; System; Tablets; Target Populations; Technology; Testing; Time; Trail Making Test; Translating; Visit; Walking; base; clinical Diagnosis; cognitive performance; cognitive testing; college; commercialization; cost; design; early screening; executive function; experience; fall risk; flexibility; foot; frailty; innovation; instrument; kinematics; mental state; meter; mild cognitive impairment; motor impairment; novel; nutrition; older patient; phase 1 study; point of care; processing speed; prototype; recruit; research clinical testing; sensor; software development; success; tool; virtual; virtual reality; visual search; wearable device; wearable technology

ABSTRACT The recent shift in Alzheimer’s disease (AD) clinical research from clinical diagnosis toward the goal of developing neuroprotective therapies has highlighted the need for a robust and rapidly-administered cognitive assessment tool capable of identifying individuals in the earliest stages of cognitive decline and measuring subtle changes in cognitive-motor performance over time. In this context, physical frailty together with cognitive impairment (known as ‘cognitive frailty’) is shown to be a strong and independent predictor of cognitive decline over time. The International Association of Gerontology and Geriatrics, as well as The International Academy on Nutrition and Aging have recommended the use of cognitive frailty measurement for determining pathways of MCI progression toward dementia/AD, and loss of independence. We have recently developed a novel cognitive frailty measurement tool that is based on a combination of a wearable sensor attached to patient’s shin and virtual reality software. The assessment performed using this platform is the Instrumented Trail Making Task or iTMT . This innovative tool for objective and simultaneous assessment of both motor and cognitive performance is used to examine the ability of the patient to execute a trail-making task in a virtual environment. The assessment is based on measuring the execution time and user performance during multiple tasks that involve visual search, scanning, speed of processing, mental flexibility, and executive function. In performing each task, motor performance is quantified by measuring ankle velocity and cognitive performance is quantified by assessing motor-planning error, working memory, and time needed to complete the task. In our pilot study, which was recently published in Gerontology, we demonstrated that iTMT can be used to assess cognitive-motor performance and identify aMCI and AD in older adults. Furthermore, we have demonstrated the ability of iTMT to determine frailty status. The iTMT could be used as an alternative test to the dual-task walking test to assess and quantify cognitive frailty in older adults. The unique benefits of the proposed platform include objectivity, low cost, time-savings, multifaceted assessment, and being easy to use. This STTR Phase I study aims to transfer this innovative and patented technology from Baylor College of Medicine to BioSensics LLC for further development, clinical testing, and commercialization. BioSensics is a privately-held biomedical firm specialized in wearable technologies for healthcare, with a proven record of rapidly transitioning governmental research funding into commercialized medical devices and technologies. The iTMT product proposed here will be added to the current line of point-of-care assessment tools commercialized by BioSensics, which includes devices for gait and fall risk (LEGSys), balance (BalanSens) and Frailty (Frailty Meter).

抽象的 阿尔茨海默氏病（AD）临床研究最近从临床诊断转变为 开发神经保护疗法已经强调了需要坚固且迅速管理的认知需求 评估工具能够在认知和测量的伯爵阶段识别个人 在这种情况下，认知运动的微妙变化。 认知障碍（称为“认知脆弱”）被证明是强大而特权 随着时间的推移，认知能力下降。 国际营养与衰老学院建议使用认知脆弱的测量方法 确定MCI向痴呆/AD的进展以及失去独立性的途径。 我们最近开发了一种新颖的认知特许经营脆弱的测量工具工具，该工具以一种结合 可穿戴的传感器连接到患者的Shin和虚拟现实软件上。 平台是仪器制造任务或ITMT。 评估运动和认知表现都用于检查患者执行的能力 在虚拟环境中的拖尾任务是基于执行时间的 在多个任务中的性能，包括视觉搜索，扫描，处理速度，心理灵活性， 和执行每个任务时，通过测量踝关节量的运动性能 通过评估运动规划误差，工作记忆和所需时间来量化认知性能 在我们的试点研究中完成该任务。 ITMT可用于评估认知运动的表现并识别老年人的AMCI和AD。 此外，我们已经证明了ITMT确定iTMT的能力。 双重任务步行测试的替代测试，以评估和量化老年人的认知脆弱性 拟议平台的独特好处包括目标，低成本，节省时间，多面评估， 并且易于使用。 该STTR I阶段研究旨在转移以转移从贝勒学院转移专利技术 Biosensics LLC的医学用于进一步开发，临床测试和商业化 私有生物医学秘密公司专门从事可穿戴技术的医疗保健技术，并具有可靠的记录 迅速将政府研究资金转变为商业化的医疗设备和技术。 提议的ITMT产品将添加到当前的护理评估工具中 由生物密度商业化，其中包括步态和跌倒风险的设备（腿），平衡（Balansens） 和脆弱的（周年纪念电表）。